Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGB-9768 in Healthy Volunteers
NCT06501573Phase 1Completed
- Sponsor
- SanegeneBio
- Start
- Jul 2024
- Primary completion
- May 2026
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in complement-mediated disease comparing SGB-9768 with Placebo (2 arms). Primary endpoint: Safety and tolerability of SGB-9768 at 169 days. Started Jul 2024; status: completed.
02
Drugs
SGB-9768
03
Conditions
complement-mediated disease
Beyond the preview
Go deeper on NCT06501573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06501573.